Merck, Inc.
🇵🇭Philippines
Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
Phase 3
Completed
- Conditions
- Prevention of : Herpes-Zoster
- Interventions
- Biological: Zostavax
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 759
- Registration Number
- NCT00561080
Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 943
- Registration Number
- NCT00560833
Safety Study of ProQuad® rHA in Infants (V221-037)
Phase 3
Completed
- Conditions
- VaricellaMeaslesMumpsRubella
- Interventions
- Biological: ProQuad®
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3388
- Registration Number
- NCT00560755
Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)
Phase 3
Completed
- Conditions
- Pneumococcal Infection
- Interventions
- Biological: pneumococcal 23v polysaccharide vaccine
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT00560950
Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)
Phase 3
Completed
- Conditions
- Anesthesia, General
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 52
- Registration Number
- NCT00559468
A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)
Phase 1
Completed
- Conditions
- Advanced Cancer
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 47
- Registration Number
- NCT00559182
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)
Phase 2
Completed
- Conditions
- Anesthesia, General
- Interventions
- First Posted Date
- 2007-11-02
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00552617
A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)
- First Posted Date
- 2007-11-02
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 102
- Registration Number
- NCT00552929
A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)
Phase 2
Completed
- Conditions
- Bacterial Infections; Virus Diseases
- Interventions
- Biological: AR51 (12, 10)Biological: PR51 (6, 10)Biological: PR51 (6, 15)Biological: PR51 (3, 10)
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 708
- Registration Number
- NCT00551629
A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)
Phase 2
Completed
- Conditions
- Bacterial Infections; Virus Diseases
- Interventions
- Biological: PR51 (6, 10)Biological: PENTACEL™Biological: PR51 (3, 10)Biological: AR51 (12, 10)Biological: RECOMBIVAX HB™
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 756
- Registration Number
- NCT00551915
© Copyright 2025. All Rights Reserved by MedPath